HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Korean Translation Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bigal, M. E. Articles by Lipton, R. B. Search for Related Content PubMed PubMed Citation Articles by Bigal, M. E. Articles by Lipton, R. B. Related Collections All Headache Migraine All epidemiology

Excessive acute migraine medication use and migraine progression

From Merck Research Laboratories (M.E.B.), Whitehouse Station, NJ; Departments of Neurology (M.E.B., R.B.L.) and Epidemiology and Population Health (R.B.L.), Albert Einstein College of Medicine, Bronx; and The Montefiore Headache Center (R.B.L.), Bronx, NY.

Address correspondence and reprint requests to Dr. Marcelo E. Bigal, 1 Merck Drive, Whitehouse Station, NJ 08889 marcelo_bigal{at}merck.com

Long considered a chronic disorder with a stable course, recent research demonstrates that, in a subgroup, migraine progresses to chronic migraine. Among the risk factors for migraine progression, acute symptomatic medication overuse (SMO) is regarded as one of the most important. Though SMO and chronic migraine are associated, several questions remain unanswered. First, the causal path is controversial (SMO as a cause or consequence). Second, it is unclear if specific classes of medication, as well as critical doses of exposures, are necessary. Herein we review this topic in the light of recent conducted research. Although several caveats exist and the data should be taken with caution, important findings are as follows: 1) Opiates are associated with migraine progression; critical dose of exposure is around 8 days per month, and the effect is more pronounced in men. 2) Barbiturates are also associated with migraine progression. Critical dose of exposure is around 5 days per month and the effect is more pronounced in women. 3) Triptans induced migraine progression in those with high frequency of migraine at baseline (10–14 days per month), but not overall. 4) Anti-inflammatory medications were protective in those with <10 days of headache at baseline, and, as triptans, induced migraine progression in those with high frequency of headaches. Accordingly, specific classes of medications are associated with migraine progression, and high frequency of headaches seems to be a risk factor for chronic migraine regardless of medication exposure.

GLOSSARY: AMPP = American Migraine Prevalence and Prevention study; CDH = chronic daily headache; CM = chronic migraine; EM = episodic migraine; ICHD = International Classification of Headache Disorders; NDPH = new daily persistent headache; NSAID = nonsteroidal anti-inflammatory drugs; OTC = over the counter; RR = risk ratio; SMO = symptomatic medication overuse; TM = transformed migraine.

Disclosure: Dr. Bigal is a full-time employee of Merck Research Laboratories. Dr. Bigal and Dr. Lipton conducted research and/or were in the advisory board and/or were in the speakers bureau of several pharmaceutical companies that market migraine medications.

Received July 8, 2008. Accepted in final form August 22, 2008.

This article has been cited by other articles:

				N. K. Sethi EXCESSIVE ACUTE MIGRAINE MEDICATION USE AND MIGRAINE PROGRESSION Neurology, September 1, 2009; 73(9): 738 - 738. [Full Text] [PDF]

Correspondence: